HC Wainwright & Co. Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Ananda Ghosh downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price target from $87 to $72.
HC Wainwright & Co. analyst Ananda Ghosh downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price target from $87 to $72.